Atai and Recognify's schizophrenia drug fails to meet main goal in trial

 Atai Life Sciences and its partner Recognify Life Sciences said on Friday their experimental drug did not meet the main goal in a mid-stage trial for patients with cognitive impairment linked to schizophrenia.

U.S.-listed shares of atai fell about 14% in extended trading.

https://kfgo.com/2025/07/25/atai-life-sciences-schizophrenia-drug-fails-to-meet-main-goal-in-mid-stage-trial/